Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure patients could go home sooner with injectable diuretic

NCT ID NCT07018297

Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether people hospitalized for acute heart failure can be discharged early and continue treatment at home using a subcutaneous injection of furosemide (a diuretic) instead of staying in the hospital for standard IV diuretics. About 250 adults will be randomly assigned to either early discharge with the injection or standard care. The main goal is to see if the early discharge approach is no worse than standard care in terms of days alive and out of the hospital after 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
subcutaneous furosemide (Lasix ONYU)
What this could lead to
If it works, this could allow some heart failure patients to go home earlier and continue treatment there, reducing hospital stays without increasing risks.
What could go wrong
This is a relatively small trial (250 people) and only tests non-inferiority, not superiority. The approach may not work for all patients, and there is a risk of complications from self-administered injections at home.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Within 48 hours of inpatient stay OR ED presentation for HF with plans for admission OR observation stay/short-stay hospitalization for HF * Expected to require at least 24 additional hours of IV diuretics * Adequate home environment for self-care * Patient or caregiver capable of operating subcutaneous delivery device Exclusion Criteria: * Cognitive impairment preventing informed consent * Geographic barriers to follow-up * Pregnancy or breastfeeding * IV furosemide requirement \>250mg/day * eGFR \<20 mL/min/1.73m2 * Type 1 myocardial infarction during index admission * End-stage HF with receipt or consideration of heart transplant or LVAD or requiring inotropic or mechanical circulatory support * Potassium \<3.0 or \>6.0 mmol/L or sodium \<125 mmol/L

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute decompensated heart failure Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor Scott and White Health System

    Dallas, Texas, 75246, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.